RxDoctor Payments DataLook up a doctor →

Vishal Gupta, MD

Interventional Cardiology · Kalamazoo, MINPI 1861507824

Payments from drug & device makers

$509,516in general payments, 2019–2025

Across 1,167 payments — averaging $436.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$122K
  • Boehringer Ingelheim$88K
  • Amgen$61K
  • Abbott$59K
  • Johnson & Johnson$35K
  • E.r. Squibb & Sons, L.L.C.$23K
  • plus $121K from 52 others

What the payments were for

  • Consulting fees$10,8154%
  • Speaking & faculty fees$222,22976%
  • Travel & lodging$32,09811%
  • Food & beverage$27,5769%
  • Education$2190%
  • Entertainment$440%
  • Other$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$509,516 in reported general payments places this provider in the 90th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$196,162
Medicare patients
756
Services billed
1,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten19$155,813
EliquisApixaban134$135,023
EntrestoSacubitril/Valsartan67$99,931
XareltoRivaroxaban76$93,982
JardianceEmpagliflozin72$81,212
Repatha SureclickEvolocumab13$14,095
NexlizetBempedoic Acid/Ezetimibe11$7,998
Praluent PenAlirocumab14$6,491
Rosuvastatin Calcium185$4,463
Metoprolol Succinate204$4,230
Ranolazine ErRanolazine23$4,039
ClopidogrelClopidogrel Bisulfate189$3,618
Atorvastatin Calcium187$3,086
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$2,448
Ezetimibe52$2,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$22,560$155,81319 claims
PfizerEliquis$19$135,023134 claims
NovartisEntresto$122,165$99,93167 claims
Johnson & JohnsonXarelto$35,285$93,98276 claims
Boehringer IngelheimJardiance$88,347$81,21272 claims
Esperion Therapeutics, Inc.Nexlizet$3,830$7,99811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →